VII Heart Failure Summit 2022. Heart Failure, Cardiomyopathies and Pulmonary HT

VII International Heart Failure Summit

Liotta Conference

Heart Failure, Cardiomyopathies and Pulmonary Hypertension Management in the Polypharmacy and Device Era

HYBRID CONFERENCE

Virtual and In-Person

October 17-October 21, 2022

Polypharmacy 1, 2, 3, 4, 5 ,6 …. Therapies in Heart Failure

Cardiometabolic disease, Diabetes, Kidney and Heart Failure (iSGLT2, GLP-1 agonist)

Ablattion or not Ablation of atrial fibrillation in Heart Failure?

Heart Failure as prothrombotic disease

Cardiomyopathies and Heart Failure

Focus in

Amyloidosis. Newer approaches. Early diagnosis and treatment

Devices and remote monitoring for HFREF & HFPEF

Preserved EF HF. Different Phenotypes. Newer therapies.

New Cardiogenic Shock Guidelines

Novel strategies in Pulmonary Hypertension

Cardio-Oncology. Approach in cancer patients

Interventional Heart Failure

Percutaneous Valvular Interventions

Arrhythmias management in Heart Failure

Multimodality imaging in HF.

Hypertrophic Cardiomyopathy (HCOM/HCM)

Percutaneous and Durables Ventricular Assist Devices

Total Artificial Heart

Alejandro (Alex) Barbagelata, MD, FAHA, FSCAI, FICA, MTSAC
Program Director

Dr. Barbagelata is an invasive cardiologist with Heart Failure longstanding expertise. He was past director of the Heart failure, assist devices and Transplant at University of Texas medical branch. Professor of Medicine/Cardiology Duke University School of Medicine and Board of Directors of DUCCS (Duke University Cardiovascular Society). Member of the International Speaker Bureau of the American Heart Association. He Co-direct the Heart Failure program at the Catholic University and has privileges in several centers in private practice